Multi-omics Approach to Understanding PD-L1 Resistance in Cancer

Presented By: Moshe Sade Feldman PhD & Russell Jenkins MD, PhD

Speaker Biography: Moshe Sade Feldman is an Instructor in Medicine and the Director of the Translational Cancer Immunology lab at Massachusetts General Hospital Cancer Center. His research focus is the development of new, unbiased strategies to understand basic immune processes and immune-mediated diseases, with an emphasis on the immune system and personal medicine.

Russell Jenkins is an Assistant Professor and Member of the Faculty of Medicine, Massachusetts General Hospital Cancer Center. His research focus is understanding why immunotherapy works for some patients and not others. The Jenkins laboratory uses sophisticated tools to investigate the complex and dynamic interactions between cancer cells and the immune system.

Webinar: Multi-omics Approach to Understanding PD-L1 Resistance in Cancer

Webinar Abstract: Although immune-based therapies targeting the inhibitory receptors (PD-L1, PD1, and CTLA4) are proven to be effective to treat cancer, some patients do not respond, or stop responding within the first year of therapy. Identifying the underlying mechanisms associated with these variable response rates remains an important open research challenge in clinical oncology. Join this free webinar to learn how researchers are integrating cell sorting, RNA sequencing, ex-vivo phenotype profiling, and patient-derived xenografts to study the mechanisms of PD-L1 resistance in cancer.

Earn PACE Credits:

LabRoots on Social:
SnapChat: labroots_inc